ART105

ART105 is an investigational small interfering RNA (siRNA) therapeutic being developed by Anto Biopharma (Suzhou Anto Biopharmaceuticals) for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The drug is designed to target and silence a specific gene involved in the pathogenesis of ADPKD, a genetic disorder characterized by the growth of numerous cysts in the kidneys. ART105 is formulated for subcutaneous injection and utilizes a delivery platform (likely GalNAc-conjugation or similar) to ensure targeted delivery to the relevant tissues. It is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamic effects in healthy adult participants, with a focus on biomarkers associated with ADPKD progression.